BNP Paribas Funds Health Care Innovators Privilege CapitalisationRegister to Unlock Ratings |
Performance History | 30/04/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 16.7 | 12.5 | 7.8 | -1.2 | 7.6 | |
+/-Cat | -0.8 | 3.0 | 12.5 | 2.0 | 5.7 | |
+/-B’mrk | - | -5.7 | 2.0 | 1.4 | 2.8 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 14/05/2024 | EUR 367.41 | |
Day Change | 0.26% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0823417224 | |
Fund Size (Mil) 14/05/2024 | EUR 1651.81 | |
Share Class Size (Mil) 14/05/2024 | EUR 49.42 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 29/04/2024 | 1.08% |
Investment Objective: BNP Paribas Funds Health Care Innovators Privilege Capitalisation |
Increase the value of its assets over the medium term by investing in healthcare innovative companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Jon Stephenson 02/05/2016 | ||
Christian Fay 09/07/2018 | ||
Inception Date 17/05/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care 10/40 NR EUR | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BNP Paribas Funds Health Care Innovators Privilege Capitalisation | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.19 |
UnitedHealth Group Inc | Healthcare | 6.95 |
AstraZeneca PLC | Healthcare | 6.27 |
Sanofi SA | Healthcare | 5.15 |
Boston Scientific Corp | Healthcare | 4.78 |
Increase Decrease New since last portfolio | ||
BNP Paribas Funds Health Care Innovators Privilege Capitalisation |